[Zhou Jun] local rights have been cancelled, and the central government has uniformly formulated the national basic drug catalogue; Fu Ren pharmaceutical industry has delayed the payment of dividends, and has been inquired twice by the Shanghai Stock Exchange; Ma Yinglong's Lipstick has become popular, and netizens have joked about "one drug for two purposes"

This week's highlights: 1 The local basic medicine medical insurance catalogue will be cancelled soon, and the decision right will return to the National Medical Insurance Bureau; 2 The scientific and Technological Innovation Board will open, and the medical equipment enterprises will be centralized; 3 The auxiliary benevolent medicine industry will delay the payment of dividends, and it will be inquired twice by the Shanghai Stock Exchange; 4 Ma Yinglong's lipstick will be popular, and netizens will tease about "dual use of one medicine" On July 22, the State Medical Insurance Bureau issued the heavyweight document opinions on establishing the management system of medical insurance treatment list (Draft for comments) (hereinafter referred to as the draft for comments) According to the opinion draft, the State formulates the directory of national basic medical insurance drugs in a unified way, and all localities strictly follow the directory of national basic medical insurance drugs In principle, they are not allowed to make their own directory or use alternative methods to add drugs in the directory According to the requirements of eliminating increment and standardizing stock, in principle, all localities shall not issue policies and measures beyond the scope of authorization of the list The provincial people's Government shall take the overall responsibility for the policies and measures that are not consistent with the list issued in the past, and the policy issuing department shall take the lead in detail In principle, the clearing and standardizing shall be completed within three years and shall be connected with the national policies That is to say, the decision-making power of the basic medical insurance drug catalog has been basically returned to the central government, the original 15% adjustment power of the local government has been cancelled, and the local medical insurance catalog is about to be cancelled In addition, the document stipulates that "in principle, the policies and measures that do not conform to the list issued in the past will be cleaned up and standardized within three years", and the cancellation of the local medical insurance catalogue will have three years of "Probation" For manufacturers, if their varieties are not included in the national medical insurance catalog, it is difficult to obtain the large amount of medical insurance by supplementing the local catalog In the future, they need to reconsider their product strategies and only take the way of self funded drugs On July 24, the ninth meeting of the Central Committee for comprehensively deepening reform was held, and "opinions on promoting the inheritance and innovation of traditional Chinese medicine" and "pilot work plan for the construction of regional medical center" were reviewed and approved It was pointed out at the meeting that adhering to the principle of emphasizing both Chinese and Western medicine and promoting the complementary and coordinated development of Chinese medicine and Western medicine are the significant advantages of China's health and health undertakings We should improve the service system of traditional Chinese medicine, promote the high-quality development of the cause and industry of traditional Chinese medicine, strengthen the construction of the talent team of traditional Chinese medicine, promote the inheritance and open and innovative development of traditional Chinese medicine, reform and improve the management system and mechanism of traditional Chinese medicine, and play the special role of traditional Chinese medicine in disease treatment and prevention The meeting stressed that the main task of carrying out the pilot construction of regional medical centers is to select a number of high-quality medical institutions in areas with rich medical resources, such as Beijing and Shanghai, and to build regional medical centers in areas with high patient outflow and relatively weak medical resources by building sub centers and branches, promoting multi-point practice of doctors, etc., and making full use of artificial intelligence, big data, etc Advance technology, promote the group development of high-quality medical resources, and better meet the needs of mass medical services Through the above content, it is not difficult to see that the government attaches the same importance to Chinese and Western medicine In the current era of Western medicine, the state gives more opportunities and markets to traditional Chinese medicine as much as possible, hoping that Chinese and Western medicine can complement each other, and also hoping that this can not only preserve the inheritance of traditional Chinese medicine, but also make the medical cause progress It is a hot news in the industry that 13 sub bureaus of Jiangsu Province have been listed The regulatory network should focus on the source On July 23, the licensing conference of inspection sub bureaus of Jiangsu drug regulatory bureau was held in Nanjing This marks another substantive and decisive step in deepening the reform of market supervision and improving the drug supervision system in Jiangsu Province, which is of great significance for ensuring drug safety, promoting the development of the pharmaceutical industry and benefiting the people's livelihood At the meeting, 13 inspection sub bureaus were awarded by the general administration Inspection branches have been set up in 13 districts and cities in Jiangsu Province (Nanjing, Wuxi, Xuzhou, Changzhou, Suzhou, Nantong, Lianyungang, Huai'an, Yancheng, Yangzhou, Zhenjiang, Taizhou and Suqian) At the same time, it also emphasizes three points: the establishment of inspection sub bureaus is a key link in strengthening the drug safety regulatory network from the perspective of regulatory system; a key way to ensure the source of drug safety from the perspective of regulatory objects; and a key step in improving the drug regulatory capacity from the perspective of regulatory effectiveness Opening of science and technology innovation board, centralized station of medical equipment enterprises On July 22, the high-profile scientific and technological innovation board was launched Medical equipment enterprises led the scientific and technological innovation board on the basis of many favorable policies, ushering in the era of innovative medical equipment According to the statistics, there are 32 pharmaceutical enterprises in the list of scientific and technological innovation board, including 15 Medical equipment enterprises, which are mainly concentrated in imaging equipment, in vitro diagnosis and high-value consumables Three plates In today's medical equipment enterprises in the market, they are faced with the situation of monopoly of import enterprises If they want to develop, they naturally need to face the "import substitution" This also means that our medical equipment enterprises should directly face the challenge arena of transnational giants Under the existing technology gap, in addition to continuous innovation and overtaking, they also need to take advantage of localization advantages and firmly occupy the sales channels At the same time, medical equipment enterprises are also an industry that needs constant investment, innovation and iteration A large number of consulting needs can only rely on landing in the capital market to obtain financing, so as to continuously achieve product upgrading and strive to lay network channels This is also the core demand of the enterprise, which is why medical equipment enterprises focus on scientific and technological innovation But at present, there are still many risks and tests in medical devices The government, market, market and technology are all barriers But if overcome, the development of enterprises will be brilliant After the fortune list was released, China finally had a long face on July 22, and the latest Fortune 500 list was newly released In the pharmaceutical industry, there are 11 enterprises at home and abroad on the list Among them, 9 are multinational pharmaceutical enterprises and 2 are domestic enterprises In terms of operating revenue, "Maxon" ranked first in medicine with a revenue of $214.319 billion, while "Medtronic" ranked last in medicine category also had a revenue of $29.953 billion It is worth noting that there are two Chinese pharmaceutical companies on the world top 500 list Among them, China Resources Co., Ltd., including China Resources Pharmaceutical Co., Ltd., ranked No 80 with us $91.986 billion, up 6 places compared with the previous year; China Pharmaceutical Group, ranked No 169, achieved US $59.98 billion in operating revenue, up 25 places compared with the previous year This means that Chinese pharmaceutical enterprises have more power to enter the world top 500 In fact, 129 of the world's top 500 enterprises are from China, which is the first time in history to surpass the United States (121), which also means that this is a historic turning point In recent years, the rapid expansion of domestic demand market has indeed provided an important platform for large Chinese enterprises to continue to grow Secondly, strategic restructuring and changes in China's macro-economy have also become the driving force for the collective rise of Chinese companies But individual can never represent the collective, one person has money, can not represent the living standard of the whole people, how to make the collective bigger and stronger, how to effectively compete with the transnational Perhaps it is the more pressing issue Some experts also said, "in order to truly become a multinational enterprise, we must make use of global resources The earlier we start the global sales layout, market layout and innovation layout, the greater the advantage we can have." In the early stage, Chinese pharmaceutical enterprises went to sea mainly for APIs, which provided continuous power for other innovation providers Because of this, Chinese enterprises are not strengthening their competitiveness, but losing their competitive advantage Therefore, at present, the most urgent thing is only the innovation ability and operation ability of Chinese enterprises "The enterprise information assisted benevolence pharmaceutical industry delayed paying dividends and was inquired twice by the Shanghai Stock Exchange On July 16, 2019, Furen pharmaceutical announced the notice on the implementation of 2018 annual equity distribution, which was originally scheduled to be issued on July 22, 2019 The failure to pay in place triggered heated discussion among netizens: "holding 1.8 billion cash, but not taking out more than 60 million yuan of dividends, worthy of the name of the Iron Rooster." The SSE also took this opportunity to intervene in the event and asked Fu Ren to explain the specific process of dividend; the specific reasons for failure to dividend; the company's current capital situation; the company's and subsidiary's capital balance and its deposit methods and restrictions; verify and explain the capital transactions and guarantees with the controlling shareholders, actual controllers and their related parties Netizens speculated that there might also be major shareholders encroaching on the assets of listed companies Otherwise, how could it happen? On the one hand, since June, Fu Ren pharmaceutical industry has suddenly issued a concentrated announcement that 13 shares of controlling shareholders have been frozen, and Zhu Wenchen, a major shareholder, has been frozen continuously On the other hand, Fu Ren pharmaceutical industry holds a large amount of money but can't give dividends to shareholders It's not forbidden for people to wonder where so much money has gone What's more, it doubts Zhu Wenchen, chairman of the board of directors There may be something wrong with the situation, which indirectly causes the rupture of the company's capital chain Although there is no evidence, there is no reason for speculation On the 25th, Fu Ren replied to the Shanghai Stock Exchange, saying that the balance on his account was only 3.78 million yuan of available funds, with a limited amount of 1.23 billion yuan At present, 97% of the company's cash is limited, and the capital pressure is large Daily production and operation may be affected by this, but it didn't really explain why the 1.2 billion fund disappeared All kinds of information circulated on the Internet directly refers to Furen, which indirectly reflects that Furen pharmaceutical industry has been riddled with holes in capital operation, and the second inquiry of Shanghai Stock Exchange is officially to confirm this As long as Furen can "kill rumors" in this inquiry, it is impossible to top again The lipstick produced by Ma Yinglong, famous for hemorrhoids cream, has become popular on the Internet recently Netizens have said that this is the "king of cross-border" this year Ma Yinglong official said that the company is based on Ma Yinglong's great health industry chain, relying on the user's recognition of Ma Yinglong's brand, and is indeed doing functional cosmetics extension But this customized lipstick standard, the market response is so beyond expectations, and it will not be ruled out that it will be mass produced in the future, but it is not the company's core key product for the time being In the past, the main battlefield of Ma Yinglong was in the terminal of retail drugstores, of which the well-known Ma Yinglong musk Hemorrhoid Cream and musk hemorrhoid suppository accounted for 40% of the whole market, which was far ahead of the rest Netizens even joked that half of Chinese people rely on Ma Yinglong for their buttocks Starting from ophthalmic medicine, Babao formula is the exclusive formula, which has derived a variety of products such as Ma Yinglong's Musk Hemorrhoid Cream, musk hemorrhoid suppository, Longzhu ointment, Babao eye cream, etc at present, it is gradually involved in the field of health and cosmetics But not the first to eat crabs The transformation of pharmaceutical industry is numerous, and the most familiar one is "Yunnan Baiyao toothpaste" According to the 2018 annual report of Yunnan Baiyao, the business revenue of health products business department is more than 4.4 billion yuan, accounting for 16.72% of the company's total revenue With the rapid growth of toothpaste business, the market share ranks the second in China, which is extremely successful In fact, such behavior of pharmaceutical companies is due to the increasingly strict drug supervision Pharmaceutical companies want to break through the original ceiling, the usual practice is unlikely, they choose to transform other or promising, and the acceptance of rapid consumption and daily chemical industry is generally high With the advantages of brand and resources, pharmaceutical enterprises will get more growth points in the fields of health food, beverage, cosmetics, etc., which is undoubtedly a very good strategy.